Search research articles
Contact Us
Filters
Showing results (681-690 of 962) with videos related to
Page
of 97
Sort By:
Lancet (London, England)
|
March 15, 2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Francesco Costa, David van Klaveren, Stefan James, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
March 14, 2008
Risk factor profile and management of cerebrovascular patients in the REACH Registry
Joachim Röther, Mark J Alberts, Emmanuel Touzé, et al.
European Heart Journal
|
March 7, 2023
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 30, 2022
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial
Philippe Gabriel Steg, Deepak L Bhatt, Stefan K James, et al.
Diabetes, Obesity & Metabolism
|
December 6, 2017
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
Petra El Khoury, Ronan Roussel, Frederic Fumeron, et al.
American Heart Journal
|
June 2, 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events
Harvey D White, Ralph A H Stewart, Anthony J Dalby, et al.
Journal of the American College of Cardiology
|
November 5, 2013
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention)
Philippe Généreux, Gregg W Stone, Robert A Harrington, et al.
European Journal of Heart Failure
|
December 22, 2023
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
Siddharth M Patel, David A Morrow, Andrea Bellavia, et al.
European Journal of Preventive Cardiology
|
January 18, 2018
The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up
Michel Komajda, Mathieu Kerneis, Luigi Tavazzi, et al.
Circulation. Cardiovascular Interventions
|
August 23, 2021
Compared Outcomes of ST-Segment-Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial
Pierre Denormandie, Tabassome Simon, Guillaume Cayla, et al.
Page
of 97
Search research articles
Search
Showing results (681-690 of 962) with videos related to
Sort By:
Page
of 97
Lancet (London, England)
|
March 15, 2017
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Francesco Costa, David van Klaveren, Stefan James, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
March 14, 2008
Risk factor profile and management of cerebrovascular patients in the REACH Registry
Joachim Röther, Mark J Alberts, Emmanuel Touzé, et al.
European Heart Journal
|
March 7, 2023
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 30, 2022
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial
Philippe Gabriel Steg, Deepak L Bhatt, Stefan K James, et al.
Diabetes, Obesity & Metabolism
|
December 6, 2017
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
Petra El Khoury, Ronan Roussel, Frederic Fumeron, et al.
American Heart Journal
|
June 2, 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events
Harvey D White, Ralph A H Stewart, Anthony J Dalby, et al.
Journal of the American College of Cardiology
|
November 5, 2013
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention)
Philippe Généreux, Gregg W Stone, Robert A Harrington, et al.
European Journal of Heart Failure
|
December 22, 2023
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
Siddharth M Patel, David A Morrow, Andrea Bellavia, et al.
European Journal of Preventive Cardiology
|
January 18, 2018
The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up
Michel Komajda, Mathieu Kerneis, Luigi Tavazzi, et al.
Circulation. Cardiovascular Interventions
|
August 23, 2021
Compared Outcomes of ST-Segment-Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial
Pierre Denormandie, Tabassome Simon, Guillaume Cayla, et al.
Page
of 97